These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6160015)

  • 21. Circadian changes in procainamide and N-acetylprocainamide kinetics in the rat.
    Bruguerolle B; Jadot G
    J Pharm Pharmacol; 1985 Sep; 37(9):654-6. PubMed ID: 2416904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cimetidine inhibits renal procainamide clearance.
    Christian CD; Meredith CG; Speeg KV
    Clin Pharmacol Ther; 1984 Aug; 36(2):221-7. PubMed ID: 6204803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical pharmacology of procainamide and its active metabolite -N-acetylprocainamide].
    Matusewicz W; Orszulak DE
    Przegl Lek; 1984; 41(5):379-83. PubMed ID: 6206523
    [No Abstract]   [Full Text] [Related]  

  • 25. Acetylprocainamide therapy in patients with previous procainamide-induced lupus syndrome.
    Kluger J; Drayer DE; Reidenberg MM; Lahita R
    Ann Intern Med; 1981 Jul; 95(1):18-23. PubMed ID: 6166229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect kinetics of N-acetylprocainamide-induced QT interval prolongation.
    Piergies AA; Ruo TI; Jansyn EM; Belknap SM; Atkinson AJ
    Clin Pharmacol Ther; 1987 Jul; 42(1):107-12. PubMed ID: 2439251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical pharmacology and antiarrhythmic efficacy of acetylprocainamide in patients with arrhythmias.
    Kluger J; Drayer D; Reidenberg M; Ellis G; Lloyd V; Tyberg T; Hayes J
    Am J Cardiol; 1980 Jun; 45(6):1250-7. PubMed ID: 6155064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease.
    Kates RE; Jaillon P; Rubenson DS; Winkle RA
    Clin Pharmacol Ther; 1980 Jul; 28(1):52-7. PubMed ID: 6156049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levofloxacin and ciprofloxacin decrease procainamide and N-acetylprocainamide renal clearances.
    Bauer LA; Black DJ; Lill JS; Garrison J; Raisys VA; Hooton TM
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1649-51. PubMed ID: 15793163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of procainamide N-acetylation in the rat in vivo and in the perfused rat liver preparation.
    Pang KS; Huang JC; Finkle C; Kong P; Cherry WF; Fayz S
    Drug Metab Dispos; 1984; 12(3):314-22. PubMed ID: 6203693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Theoretical basis for interest in acetylprocainamide and clinical experiences with this new antiarrhythmic agent.
    Drayer D; Kluger J; Reidenberg M; Lahita R
    Drug Metab Rev; 1979; 10(2):239-46. PubMed ID: 95247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of procainamide in chronic ambulatory peritoneal dialysis: report of a case.
    Kroboth PD; Mitchum K; Puschett JB
    Am J Kidney Dis; 1984 Jul; 4(1):78-9. PubMed ID: 6204527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-Acetylprocainamide pharmacokinetics in functionally anephric patients before and after perturbation by hemodialysis.
    Stec GP; Atkinson AJ; Nevin MJ; Thenot JP; Ruo TI; Gibson TP; Ivanovich P; del Greco F
    Clin Pharmacol Ther; 1979 Nov; 26(5):618-28. PubMed ID: 91468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphic acetylation procainamide in man.
    Reidenberg MM; Drayer DE; Levy M; Warner H
    Clin Pharmacol Ther; 1975 Jun; 17(6):722-30. PubMed ID: 237647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mandibular and parotid salivary excretion of procainamide and N-acetylprocainamide after intravenous administration of procainamide to rats.
    Watanabe J; Koyama I; Iwamoto K; Ozeki S
    J Pharm Pharmacol; 1987 Nov; 39(11):912-6. PubMed ID: 2448449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
    Zema MJ; Mirando T
    Angiology; 1983 Jan; 34(1):32-9. PubMed ID: 6186164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure.
    Arimori K; Nakano M
    J Pharmacobiodyn; 1988 Jul; 11(7):504-11. PubMed ID: 2460613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.
    Coyle JD; Boudoulas H; Lima JJ
    Biopharm Drug Dispos; 1991 Nov; 12(8):599-612. PubMed ID: 1724922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the immunomodulator tilorone on the in vivo acetylation of procainamide in the rat.
    Svensson CK; Knowlton PW
    Pharm Res; 1989 Jun; 6(6):477-80. PubMed ID: 2474808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Procainamide and N-acetylprocainamide kinetics investigated simultaneously with stable isotope methodology.
    Dutcher JS; Strong JM; Lucas SV; Lee WK; Atkinson AJ
    Clin Pharmacol Ther; 1977 Oct; 22(4):447-57. PubMed ID: 902457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.